At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 543 enrolled
Drug / intervention
Rosuvastatin +1 moredrug
Likely dose
Rosuvastatin 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase 3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects
In Brief
A Phase 3 clinical trial evaluating Rosuvastatin and Placebo for Atherosclerosis. Completed, enrolled 543 participants across 24 sites.
Detailed Summary
The purpose of this study is to evaluate the effects of of rosuvastatin 20 mg compared to placebo for treating Chinese patients with subclinical atherosclerosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtherosclerosis
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartSep 2015
Primary CompletionJan 2019
TodayJul 2026
First PostedSep 10, 2015
Enrollment StartSep 17, 2015
Primary CompletionJan 29, 2019
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 10.8 years ago
Interventions
Rosuvastatindrug
20mg tablets, orally once daily for the duration of the 104-week treatment period
Placebodrug
Matching placebo tablets, orally once daily for the duration of the 104-week treatment period.